Navigation Links
Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
Date:9/14/2009

nties, particularly those inherent in the process of developing and commercializing drugs. Alexza's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in Alexza's Annual Report on Form 10-K for the year ended December 31, 2008, and Alexza's other Periodic and Current Reports filed with the Securities and Exchange Commission, including the risks under the headings: "If our product candidates fail to show a clinically significant benefit compared to placebo, they will not be approved for marketing" and "If our product candidates do not meet safety and efficacy endpoints in clinical trials, they will not receive regulatory approval, and we will be unable to market them". Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 30, 2015  Astellas today announced topline results ... efficacy and safety of intravenous (IV) and oral ... development for adults with candidemia and other invasive ... demonstrated that the trial did not meet its ... in isavuconazole-treated patients at the end of IV ...
(Date:7/29/2015)... 2015 Insulet Corporation (NASDAQ: PODD ), ... OmniPod ® Insulin Management System, today announced preliminary ... 2015. The Company also announced that it will postpone ... and conference call from Thursday, July 30, as originally ... Highlights: , Preliminary second quarter ...
(Date:7/29/2015)... MONICA, Calif. , July 29, 2015  UBM ... the San Diego Marriott Marquis & Marina on September ... medical device industry. A highlight of the Business Development ... Financial Backing from Different Types of Investors, featuring ... & Johnson Development Corporation; Brent Ahrens , Partner, ...
Breaking Medicine Technology:Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5Insulet Reports Preliminary Second Quarter 2015 Revenue Results 2Insulet Reports Preliminary Second Quarter 2015 Revenue Results 3Insulet Reports Preliminary Second Quarter 2015 Revenue Results 4Insulet Reports Preliminary Second Quarter 2015 Revenue Results 5MEDevice San Diego Offers Tips on Securing Financial Backing from Investors 2
... NEW YORK, Jan. 11, 2011 WebMD Health Corp. (Nasdaq: ... private placement of $400 million aggregate principal amount of 2.50% ... of notes pursuant to the exercise in full of the ... qualified institutional buyers pursuant to Rule 144A under the Securities ...
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: ... in the development, assembly, marketing and sale of medical ... that it will participate in the Arab Health Exhibition ... 2011 at the Dubai World Trade Centre in Dubai, ...
Cached Medicine Technology:WebMD Closes Offering of 2.50% Convertible Notes Due 2018 2Dehaier Medical Announces Participation in Arab Health 2011 2
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Quintessa Medical ... Kybella is a nonsurgical treatment designed specifically for the elimination of excess ... of the first locations in the state of Wisconsin to offer this innovative treatment. ...
(Date:7/30/2015)... ... 30, 2015 , ... The Tisch Cancer Institute at Icahn ... Tisch Cancer Institute (TCI) at the Icahn School of Medicine at Mount Sinai ... elite group of 69 cancer institutions nationwide that have earned this designation, which ...
(Date:7/30/2015)... ... July 30, 2015 , ... Author Dr. Raul Llanos seeks ... in his new self-help book, “ Consciously Healing our Webs of Health, Wellbeing, Success, ... message: “If we take responsibility for ourselves, we can create better realities.” His book ...
(Date:7/30/2015)... ... 30, 2015 , ... WellSpan Health in York, Pa., has ... claims for bariatric surgery that, despite complying with national and local coverage determinations, ... nurse auditor at WellSpan Health, tells Atlantic Information Services’ (AIS) Report on Medicare ...
(Date:7/30/2015)... ... ... weight, many people place a lot of focus on the different types of food that need ... another key component to successful weight gain is knowing when to eat so that ... Gainer gives three tips on when to eat to gain weight. , The first thing ...
Breaking Medicine News(10 mins):Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 2Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 3Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 2Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 3
... but often deadly disease that can strike at any time ... and in the past was referred to as a silent ... ovarian cancer that can assist in early detection. Experts at ... of preventive methods, understand the risks and recognize potential warning ...
... that the hormone estrogen may help reverse advanced pulmonary hypertension, ... million individuals in the U.S., mostly women, and can lead ... progressive increase in blood pressure in the main pulmonary artery, ... to the lungs. The rise in pressure impairs heart function ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, ... increasing rates of drug-resistant tuberculosis, health officials say the disease ... least so far. But, they add, the ease of ... one should think they,re beyond risk. "Drug-resistant TB exists ...
... The demand for transparency through publicly available healthcare data ... and clinical data for research, and for clinical trials data ... a measurable impact on research and policy making. A new ... in Electronic Health Information at the University of Ottawa and ...
... spent glued to their PlayStation 3, Xbox 360 or Nintendo ... perhaps? Improved concentration? Superior driving skills? Over the past ... action video games such as Medal of Honor or Unreal ... in a paper published this week in the journal Frontiers ...
... HealthDay Reporter , WEDNESDAY, Sept. 14 (HealthDay News) ... jumped dramatically worldwide, from about 640,000 in 1980 to more ... Over the same period, the number of cases of ... from that cancer have declined, although in 2010 it still ...
Cached Medicine News:Health News:Early detection is key in the fight against ovarian cancer 2Health News:Early detection is key in the fight against ovarian cancer 3Health News:Estrogen treatment may help reverse severe pulmonary hypertension 2Health News:Estrogen treatment may help reverse severe pulmonary hypertension 3Health News:Officials Tackle Multidrug-Resistant TB in Europe 2Health News:Officials Tackle Multidrug-Resistant TB in Europe 3Health News:New report on creating clinical public use microdata files 2Health News:Put down that Xbox remote: FSU researcher suggests video games may not boost cognition 2Health News:Put down that Xbox remote: FSU researcher suggests video games may not boost cognition 3Health News:Breast Cancer Rates Jump Worldwide, Study Finds 2Health News:Breast Cancer Rates Jump Worldwide, Study Finds 3